MedTrace Logo

A Safety and Pharmacokinetics Study of TL-001 in Healthy Adults

NCT06867796 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-03-13

No results posted yet for this study

Summary

The goal of this study is to evaluate safety, tolerability, pharmacokinetics (PK)), pharmacodynamics (PD) and immunogenicity of single and multiple ascending dose of TL-001 in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TL-001

Intravenously administered

DRUG

Placebo

Intravenously administered

Sponsors & Collaborators

  • Tigermed Australia Pty Ltd

    collaborator UNKNOWN

  • TrueLab Biopharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2026-09-30
Completion
2026-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867796 on ClinicalTrials.gov